The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Acumen Pharmaceuticals Inc shares valued at $5,435 were purchased by Meisner Derek M on Jan 21 ’25. At $1.59 per share, Meisner Derek M acquired 3,418 shares.
Also, Siemers Eric purchased 3,219 shares, netting a total of over 5,118 in proceeds.
Before that, Barton Russell had added 2,914 shares to its account. In a trade valued at $4,962, the Officer bought Acumen Pharmaceuticals Inc shares for $1.70 each.
As published in their initiating research note from Citigroup on July 26, 2024, Acumen Pharmaceuticals Inc [ABOS] has been a Buy and the price target has been revised to $7. Analysts at Deutsche Bank started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. Earlier on May 18, 2023, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for ABOS stock.
Analyzing ABOS Stock Performance
During the last five days, there has been a surge of approximately 12.18%. Over the course of the year, Acumen Pharmaceuticals Inc shares have jumped approximately 1.74%. Shares of the company reached a 52-week high of $1.9500 on 01/06/25 and a 52-week low of $1.5300 on 01/17/25. A 50-day SMA is recorded $2.0973, while a 200-day SMA reached $2.6748. Nevertheless, trading volume fell to 0.59 million shares from 0.54 million shares the previous day.
Support And Resistance Levels for Acumen Pharmaceuticals Inc (ABOS)
According to the 24-hour chart, there is a support level at 1.6167, which, if violated, would cause prices to drop to 1.4835. In the upper region, resistance lies at 1.8466. The next price resistance is at 1.9433. RSI (Relative Strength Index) is 45.69 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0376, which suggests the price will decrease in the coming days. Percent R is at 47.62%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
